ClinicalTrials.gg
RecruitingNCT05919329Updated Oct 20, 2026

Evaluation of the Change in PSMA Expression in Prostate Cancer in Response to Hormonal Therapy

A Phase 4 interventional study of Piflufolastat and PSMA PET/CT Scan in Castration Resistant Prostate Cancer, Castration Sensitive Prostate Cancer and Prostate Adenocarcinoma, sponsored by OHSU Knight Cancer Institute. Recruiting at 1 site in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-20.

Sponsored by OHSU Knight Cancer Institute · Phase 4, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Started Jun 2024; still recruiting 2 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
80
Allocation
Non-randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 24 studies testing piflufolastat in Prostatic Neoplasms — 5 open to participants now, 9 under way, none of them phase 3. piflufolastat · Prostatic Neoplasms.

Planned enrollment
11th of 24
80 · median 55
Started
2024
with 4 others
Phase 4
5 of 24
2 open now
Registered
20th of 24
by date

Among the 24 studies testing piflufolastat in Prostatic Neoplasms, this one is the 11th largest by planned enrollment, is one of 5 that started in 2024, is one of 5 in phase 4, and was the 20th registered.

Prostatic Neoplasms

7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

5 of the 24 studies testing piflufolastat in Prostatic Neoplasms are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

About piflufolastat

piflufolastat: first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies testing piflufolastat in Prostatic Neoplasms, or all of them as a file.
02

Study summary

This clinical trial investigates the change in prostate-specific membrane antigen (PSMA) expression in response to hormonal therapy in both, Castration Sensitive Prostate Cancer (CSPC) and Castration Resistant Prostate Cancer (CRPC), and whether this change in PSMA expression changes tumor staging after therapy initiation. Understanding these effects can help define the best timing to perform the PSMA positron emission tomography (PET) relative to the start of therapy.

Read the detailed description

PRIMARY OBJECTIVE:

I. To determine the early effects (at day 8) of hormonal therapy on PSMA modulation in patients with castration sensitive prostate cancer (CSPC) and castration resistant prostate cancer (CRPC)

SECONDARY OBJECTIVES:

I. To evaluate the effects of hormonal therapy on PSMA modulation at day 28 post-therapy in patients with CSPC and CRPC

II. To evaluate whether the change in PSMA modulation after hormonal therapy initiation changes the tumor staging on PSMA PET as defined by the PROMISE V2 criteria.

EXPLORATORY OBJECTIVES:

I. To assess whether the initial change in PSMA modulation in response to hormonal therapy holds prognostic implications

II. To assess for potential correlation between the early change in PSMA modulation and tumor characteristics such as Gleason score, and site of disease.

III. To assess whether the baseline level of PSMA uptake holds prognostic implications in response to hormonal therapy

OUTLINE:

Patients will be divided (non-randomized) into 2 groups (CRPC or CSPC) and receive PSMA PET prior to start of therapy (standard of care), then again 8 days and 28 days after initiation of hormonal therapy.

Participants will be followed for up to 5 years.

03

Conditions studied

  • Castration Resistant Prostate Cancer
  • Castration Sensitive Prostate Cancer
  • Prostate Adenocarcinoma

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant or legally authorized representative (LAR) must provide written before any study-specific procedures or interventions are performed.
  • Participants must have confirmed prostate adenocarcinoma, histologically, or by combined imaging and biochemical markers.
  • Age >= 18 years. Given the nature of the disease in question, only men will be included. Members of all races and ethnic groups will be included.
  • Participants must have sites of prostate cancer showing uptake on an initial PSMA PET scan.
  • Participants are planned to receive hormonal therapy within eight weeks of the initial PSMA PET. The hormonal therapy agents include:

    • For CSPC: GnRH agonists, GnRH antagonists, first-generation antiandrogen (e.g. bicalutamide), or androgen receptor (AR)-targeted agent (e.g. Abiraterone, Enzalutamide, Apalutamide, Darolutamide)
    • For CRPC: this group of patients are typically on continuous ADT (GnRH agonists or antagonists), which will be continued, and the hormonal therapy they will be started on is an androgen receptor (AR)-targeted agent (e.g. Abiraterone, Enzalutamide, Apalutamide, Darolutamide)
  • > 3 months.
  • Cohort 1: Castration resistant prostate cancer with rising PSA (confirmed by two PSA values at least 1 week apart), testosterone \< 50 ng/dL, on continuous ADT at least 4 months, no AR targeted agent in the prior 4 months.
  • Cohort 2: Castration sensitive prostate cancer with no ADT or AR targeted agents use in the past 12 months, testosterone >50 ng/dL

Exclusion criteria

Exclusion Criteria:

  • Uncontrolled serious infection.
  • Intercurrent illness or condition that would limit compliance with study requirements.
  • Participants who have undergone any cancer treatment other than the hormonal therapy (systemic or radiation therapy) or who have started any supplements or herbal medications intended to treat cancer between the baseline PSMA PET and PSMA PET at day 28.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 4
Primary purpose
Diagnostic
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    Cohort 1: CRPC

    Patients with CRPC will receive 18F-DCFPyL PET prior to start of therapy (standard of care), then again 8 days and 28 days after initiation of hormonal therapy.

    Drug: Piflufolastat · Procedure: PSMA PET/CT Scan · Procedure: PSMA PET/MRI scan · Procedure: Biospecimen Collection · Other: Electronic Health Record Review

  • Experimental
    Cohort 2: CSPC

    Patients with CSPC will receive 18F-DCFPyL PET prior to start of therapy (standard of care), then again 8 days and 28 days after initiation of hormonal therapy.

    Drug: Piflufolastat · Procedure: PSMA PET/CT Scan · Procedure: PSMA PET/MRI scan · Procedure: Biospecimen Collection · Other: Electronic Health Record Review

Interventions

  • Given IV

    Also known as: Piflufolastat F-18, Pylarify, 18F-DCFPyL, Fluorine F 18 DCFPyL

  • ProcedurePSMA PET/CT Scan

    Undergo PSMA PET/CT

    Also known as: Prostate-Specific Membrane Antigen PET/CT, PSMA PET/CT, PSMA-Positron emission tomography/CT

  • ProcedurePSMA PET/MRI scan

    Undergo PET/MRI

    Also known as: Prostate-Specific Membrane Antigen PET/MRI, PSMA PET/MR, PSMA-Positron emission tomography/magnetic resonance imaging

  • ProcedureBiospecimen Collection

    Undergo collection of blood samples

    Also known as: Biological Sample Collection, Specimen Collection, Lab draw

  • OtherElectronic Health Record Review

    Ancillary studies

06

What researchers measure

Primary outcomes

  1. Change in maximum standardized uptake value (SUVmax) on post-therapy initiation PSMA PET (8 ± 2 days) compared to baseline.

    Evaluate the change in SUVmax between baseline and Day 8 using a paired t-test to determine how hormonal therapy affects the PSMA modulation.

    Time frame: Baseline PSMA PET up to 8 days after therapy initiation

Secondary outcomes

  1. Change in SUVmax on post-therapy initiation PSMA PET (28 ± 3 days) compared to baseline.

    Evaluate the change in SUVmax between baseline and Day 28 using a paired t-test to determine how hormonal therapy affects the PSMA modulation.

    Time frame: Baseline PSMA PET up to 28 days after therapy initiation

  2. Number of patients in whom the tumor staging changed on PSMA PET scans obtained post-therapy initiation relative to baseline PET scan

    Time frame: Baseline PSMA PET up to 28 days after therapy initiation

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2024 (actual). Primary completion is estimated for Sep 2028, 50 months after the start.

Of 52 phase 4 interventional studies under Prostatic Neoplasms, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 67. This study's planned 50 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 16, 2023
First posted
Jun 26, 2023
StartActual
Jun 25, 2024
Primary completionEst.
Sep 1, 2028
CompletionEst.
Sep 1, 2030
Last update
Oct 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Oct 20, 2026
Show all 1 update
  1. Oct 20, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT05919329
Responsible party
Nadine Mallak, MD (Principal Investigator, OHSU Knight Cancer Institute) — Principal investigator
First posted
Jun 26, 2023
Start date
Jun 25, 2024
Primary completion
Sep 1, 2028 (estimated)
Completion
Sep 1, 2030 (estimated)
Last update
Oct 20, 2026

Study contacts

Lauren Drake
Contact
RADResearch@ohsu.edu
503-494-4960
Nadine Mallak, MD
principal investigator · OHSU Knight Cancer Institute

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Piflufolastat

Start the discussion